[1] MOHD HANAFIAH K,GROEGER J,FLAXMAN AD,et al.Global epidemiology of hepatitis C virus infection:New estimates of age-specific antibody to HCV seroprevalence[J].Hepatology,2013,57(4):1333.
[2] WANG Y,LIU S,CHEN YU,et al.Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy[J].Exp Ther Med,2016,11(1):117.
[3]
[4] ORGANIZATION WH.Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[J].World Health Org,2015,23(7):485.
[5] WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:the major impact of China[J].Hepatology,2014,60(6):2099.
[6] ZHAO SH,LIU EQ,CHENG DX,et al.Comparison of entecavir and adefovir for the treatment of chronic hepatitis B[J].Brazilian J Infect Dis,2012,16(4):366.
[7] 于高平,宋春霞,刁力,等.恩替卡韦治疗慢性乙型肝炎临床疗效评价[J].肝脏,2014,19(5):384.
[8] 陈邦银,黄津.恩替卡韦治疗48周后血清HBeAg、HBsAg定量与HBV-DNA变化的相关性[J].实用中西医结合临床,2015,15(4):4.
[9] ROMERO DV,SANCHEZ CM,RODRIGUEZ SAGRADO MA,et al.Adherence to entecavir for chronic hepatitis B and correlation with effectiveness[J].Farm Hosp,2015,39(6):378.
[10] PREDA CM,BAICUS C,NEGREANU L,et al.Effectiveness of entecavir treatment and predictive factors for virologic response[J].Rev Esp Enferm Dig,2014,106(5):305.
[11] 吴娜.拉米夫定治疗慢性乙型肝炎病人的疗效及其预测因素分析[J].实用肝脏病杂志,2010,13(1):29.
[12] 柳雅,吴金明,陈梅琴.恩替卡韦治疗乙型肝炎肝硬化与慢性乙型肝炎96周的疗效[J].临床荟萃,2014,29(6):672.
[13] LEE JM,AHN SH,KIM HS,et al.Quantitative hepatitis B surface antigen and hepatitis B eantigentiters in prediction of treatment response to entecavir[J].Hepatology,2011,53(5):1486.
[14] CHANG TT,GISH RG,DE MAN R,et al.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J].N Engl J Med,2006,354(10):1001.
[15] 隋洪华,徐永红,刘涵云,等.恩替卡韦治疗慢性乙型肝炎过程中应答不佳相关因素分析[J].胃肠病学和肝病学杂志,2014,23(3):323.
[16] YUEN MF,SETO WK,FUNG J,et al.Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients:viral suppression,viral resistance,and clinical safety[J].Am J Gastroenterol,2011,106(7):1264.
[17] CAI S,YU T,JIANG Y,et al.Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load:48-week result[J].Clin Exp Med,2015,23(7):1.
[18] BECKBAUM S,CICINNATI VR,ZHANG X,et al.HepatitisBvirus induced-defect of monocyte-derived dendritic cellsleads toimpaired Thelper type 1 response in vitro,mechanisms for viral immuneescape[J].Immunology,2003,10(9):487.
[19] GINES P,ANGELI P,LENZ K,et al.European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis[J].Hepatology,2010,53(3):397.